Three Years Later: Presidential Address to MYOPAIN '04

REFERENCES

• Uveges J M, Parker J C, Smarr K L. Psychological symptoms in primary FMS syndrome: Relationship to pain, life stress and sleep disturbance. Arth Rheum 1990; 33: 1279–1283
   PubMed Web of Science ®Google Scholar
• Boscarino J A. Diseases among men 20 years after exposure to severe stress: Implications for clinical research and medical care. Psychosom Med 1997; 59(6)605–614
   PubMed Web of Science ®Google Scholar
• Amir M, Kaplan Z, Neumann L, Sharabani R, Shani N, Buskila D. Posttraumatic stress disorder, tenderness and fibromyalgia. J Psychosom Res 1997; 42(6)607–613
   PubMed Web of Science ®Google Scholar
• Cohen H, Neumann L, Haiman Y, Matar M A, Press J, Buskila D. Prevalence of post-traumatic stress disorder in FMS patients: Overlapping syndromes or post-traumatic FMS syndrome?. Semin Arthritis Rheum 2002; 32(1)38–50
   PubMed Web of Science ®Google Scholar
• Buskila D, Neumann L. Musculoskeletal injury as a trigger for fibromyalgia/posttraumatic fibromyalgia. Curr Rheumatol Rep 2000; 2(2)104–108
   PubMedGoogle Scholar
• Raphael K G, Natelson B H, Janal M N, Nayak S. A community-based survey of fibromyalgia-like pain complaints following the World Trade Center terrorist attacks. Pain 2002; 100(1–2)131–139
   PubMedGoogle Scholar
• Raphael K G, Janal M N, Nayak S. Comorbidity of FMS and posttraumatic stress disorder symptoms in a community sample of women. Pain Med 2004; 5(1)33–41
   PubMedGoogle Scholar
• Williams D A, Brown S C, Clauw D J, Gendreau R M. Self-reported symptoms before and after September 11 in patients with fibromyalgia. JAMA 2003; 289(13)1637–1638
   PubMedGoogle Scholar
• Boscarino J A, Galea S, Ahern J, Resnick H, Vlahov D. Psychiatric medication use among Manhattan residents following the World Trade Center disaster. J Trauma Stress 2003; 16(3)301–306
   PubMedGoogle Scholar
• Galea S, Resnick H, Ahern J, Gold J, Bucuvalas M, Kilpatrick D, Stuber J, Vlahov D. Posttraumatic stress disorder in Manhattan, New York City, after the September 11th terrorist attacks. J Urban Health 2002; 79(3)340–353
   PubMed Web of Science ®Google Scholar
• Galea S, Vlahov D, Resnick H, Ahern J, Susser E, Gold J, Bucuvalas M, Kilpatrick D. Trends of probable post-traumatic stress disorder in New York City after the September 11 terrorist attacks. Am J Epidemiol 2003; 158(6)514–524
   PubMed Web of Science ®Google Scholar
• Pulcino T, Galea S, Ahern J, Resnick H, Foley M, Vlahov D. Posttraumatic stress in women after the September 11 terrorist attacks in New York City. J Womens Health [Larchmt] 2003; 12(8)809–820
   PubMed Web of Science ®Google Scholar
• Ahern J, Galea S, Resnick H, Kilpatrick D, Bucuvalas M, Gold J, Vlahov D. Television images and psychological symptoms after the September 11 terrorist attacks. Psychiatry 2002; 65(4)289–300
   PubMed Web of Science ®Google Scholar
• Volpato S, Guralnik J M, Ferrucci L, Balfour J, Chaves P, Fried L P, Guralnik J M. Cardiovascular disease, interleukin-6, and risk of mortality in older women: The women's health and aging study. Circulation Feb 2001; 20, 103(7): 947–953
   Google Scholar
• Adler G K, Kinsley B T, Hurwitz S, Mossey C J, Goldenberg D L. Reduced hypothalamic-pituitary and sympathoadrenal responses to hypoglycemia in women with FMS syndrome. AmJMed 1999; 106(5)534–543
   Google Scholar
• Bremner J D, Vythilingam M, Anderson G, Vermetten E, McGlashan T, Heninger G, Rasmusson A, Southwick S M, Charney D S. Assessment of the hypo-thalamic-pituitary-adrenal axis over a 24-hour diurnal period and in response to neuroendocrine challenges in women with and without childhood sexual abuse and posttraumatic stress disorder. Biol Psychiatry 2003; 54(7)710–718
   PubMed Web of Science ®Google Scholar
• Kiecolt-Glaser J K, Preacher K J, MacCallum R C, Atkinson C, Malarkey W B, Glaser R. Chronic stress and age-related increases in the pro-inflammatory cytokine IL-6. Proc Natl Acad Sci USA 2003; 100(15)9090–9095
   PubMedGoogle Scholar
• Altier N, Stewart J. The role of dopamine in the nucleus accumbens in analgesia. Life Sci 1999; 65(22)2269–2287
   PubMedGoogle Scholar
• Altier N, Stewart J. Dopamine receptor antagonists in the nucleus accumbens attenuate analgesia induced by ventral tegmental area substance P or morphine and by nucleus accumbens amphetamine. J Pharmacol Exp Ther 1998; 285(1)208–215
   PubMedGoogle Scholar
• Wood P B. Stress and dopamine: Implications for the pathophysiology of chronic widespread pain. Med Hypotheses 2004; 62(3)420–424
   PubMed Web of Science ®Google Scholar
• Senna E R, De Barros A L, Silva E O, Costa I F, Pereira L V, Ciconelli R M, Ferraz M B. Prevalence of rheumatic diseases in Brazil: A study using the COPCORD approach. J Rheumatol 2004; 31(3)594–597
   PubMed Web of Science ®Google Scholar
• Carmona L, Ballina J, Gabriel R, Laffon A. The burden of musculoskeletal diseases in the general population of Spain: Results from a national survey. Ann Rheum Dis 2001; 60(11)1040–1045
   PubMed Web of Science ®Google Scholar
• White K P, Nielson W R, Harth M, Ostbye T, Speechley M. Does the label “fibromyalgia” alter health status, function, and health service utilization? A prospective, within-group comparison in a community cohort of adults with chronic widespread pain. Arthritis Rheum 2002; 47(3)260–265
   PubMed Web of Science ®Google Scholar
• White K P, Thompson J. Fibromyalgia syndrome in an Amish community: A controlled study to determine disease and symptom prevalence. J Rheumatol 2003; 30(8)1835–1840
   PubMedGoogle Scholar
• McBeth J, Silman A J, MacFarlane G J. Association of widespread body pain with an increased risk of cancer and reduced cancer survival: A prospective, population-based study. Arthritis Rheum 2003; 48(6)1686–1692
   PubMedGoogle Scholar
• Vaeroy H, Helle R, Forre O, Kass E, Terenius L. Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: New features for diagnosis. Pain 1988; 32: 21–26
   PubMed Web of Science ®Google Scholar
• Russell I J, Orr M D, Littman B, Vipraio G A, Alboukrek D, Michalek J E, Lopez Y, MacKillip F. Elevated cerebrospinal fluid levels of substance P in patients with the FMS syndrome. Arthritis Rheum 1994; 37(11)1593–1601
   PubMed Web of Science ®Google Scholar
• Liu Z, Welin M, Bragee B, Nyberg F. A high-recovery extraction procedure for quantitative analysis of substance P and opioid peptides in human cerebrospinal fluid. Peptides 2000; 21(6)853–860
   PubMedGoogle Scholar
• Vaeroy H, Nyberg F, Terenius L. No evidence for endorphin deficiency in FMS following investigation of cerebrospinal fluid [CSF] dynorphin A and Met-enkephalin-Arg6-Phe7. Pain 1991; 46(2)139–143
   PubMed Web of Science ®Google Scholar
• Giovengo S L, Russell I J, Larson A A. Increased concentrations of nerve growth factor in cerebrospinal fluid of patients with fibromyalgia. J Rheumatol 1999; 26(7)1564–1569
   PubMed Web of Science ®Google Scholar
• Staud R, Vierck C J, Cannon R L, Mauderli A P, Price D D. Abnormal sensitization and temporal summation of second pain [wind-up] in patients with FMS syndrome. Pain 2001; 91(1–2)165–175
   PubMed Web of Science ®Google Scholar
• Staud R, Cannon R C, Mauderli A P, Robinson M E, Price D D, Vierck C J. Temporal summation of pain from mechanical stimulation of muscle tissue in normal controls and subjects with FMS syndrome. Pain 2003; 102(1–2)87–95
   PubMed Web of Science ®Google Scholar
• Lorenz J, Grasedyck K, Bromm B. Middle and long latency somatosensory evoked potentials after painful laser stimulation in patients with FMS syndrome. Electroencephalogr Clin Neurophysiol 1996; 100: 165–168
   PubMedGoogle Scholar
• Granot M, Buskila D, Granovsky Y, Sprecher E, Neumann L, Yarnitsky D. Simultaneous recording of late and ultra-late pain evoked potentials in fibromyalgia. Clin Neurophysiol 2001; 112(10)1881–1887
   PubMed Web of Science ®Google Scholar
• Arendt-Nielsen L, Graven-Nielsen T, Svensson P, Jensen T S. Temporal summation in muscles and referred pain areas: An experimental human study. Muscle Nerve 1997; 20(10)1311–1313
   PubMedGoogle Scholar
• Desmeules J A, Cedraschi C, Rapiti E, Baumgartner E, Finckh A, Cohen P, Dayer P, Vischer T L. Neurophysiologic evidence for a central sensitization in patients with fibromyalgia. Arthritis Rheum 2003; 48(5)1420–1429
   PubMed Web of Science ®Google Scholar
• Banica B, Petersen-Felix S, Andersen O K, Radanov B P, Villiger P M, Arendt-Nielsen L, Curatolo M. Evidence for spinal cord hypersensitivity in chronic pain after whiplash injury and in fibromyalgia. Pain 2004; 107(1–2)7–15
   PubMedGoogle Scholar
• Graven-Nielsen T, Kendall S A, Henriksson K G, Bengtsson M, Sorensen J, Johnson A, Gerdle B, Arendt-Nielsen L. Ketamine reduces muscle pain, temporal summation, and referred pain in FMS patients. Pain 2000; 85(3)483–491
   PubMed Web of Science ®Google Scholar
• Sorensen J, Bengtsson A, Backman E, Henriksson K G, Bengtsson M. Pain analysis in patients with fibromyalgia: Effects of intravenous morphine, lidocaine and ketamine. Scand J Rheumatol 1995; 24: 360–365
   PubMed Web of Science ®Google Scholar
• Anderberg U M, Liu Z, Berglund L, Nyberg F. Elevated plasma levels of neuropeptide Y in female FMS patients. Eur J Pain 1999; 3(1)19–30
   PubMed Web of Science ®Google Scholar
• Staud R, Robinson M E, Vierck C J, Price D D. Diffuse noxious inhibitory controls [DNIC] attenuate temporal summation of second pain in normal males but not in normal females or FMS patients. Pain 2003; 101(1–2)167–174
   PubMed Web of Science ®Google Scholar
• Kosek E, Hansson P. Modulatory influence on somatosensory perception from vibration and hetero-topic noxious conditioning stimulation [HNCS] in FMS patients and healthy subjects. Pain 1997; 70: 41–51
   PubMed Web of Science ®Google Scholar
• Gracely R H, Petzke F, Wolf J M, Clauw D J. Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum 2002; 46(5)1333–1343
   PubMed Web of Science ®Google Scholar
• Cook D B, Lange G, Ciccone D S, Liu W C, Steffener J, Natelson B H. Functional imaging of pain in patients with primary fibromyalgia. J Rheumatol 2004; 31(2)364–378
   PubMed Web of Science ®Google Scholar
• Mountz J M, Bradley L A, Modell J G, Alexander R W, Triana-Alexander M, Aaron L A, Stewart K E, Alarcón G S, Mountz J D. Fibromyalgia in women. Abnormalities of regional cerebral blood flow in the thalamus and the caudate nucleus are associated with low pain threshold levels. Arthritis Rheum 1995; 38: 926–938
   PubMed Web of Science ®Google Scholar
• Kwiatek R, Barnden L, Tedman R, Jarrett R, Chew J, Rowe C, Pile K. Regional cerebral blood flow in fibromyalgia: Single-photon-emission computed tomography evidence of reduction in the pontine tegmentum and thalami. Arthritis Rheum 2000; 43(12)2823–2833
   PubMedGoogle Scholar
• Staud R. Fibromyalgia pain: Do we know the source?. Curr Opin Rheumatol 2004; 16(2)157–163
   PubMed Web of Science ®Google Scholar
• Wall P D, Woolf C J. Muscle but not cutaneous C-afferent input produces prolonged increases in the excitability of the flexion reflex in the rat. J Physiol 1984; 356: 443–458
   PubMed Web of Science ®Google Scholar
• Gowers W R. Lumbago: Its lessons and analogues. BMJ 1904; 1: 117–121
   PubMedGoogle Scholar
• Bengtsson A. The muscle in fibromyalgia. Rheumatology [Oxford] 2002; 41(7)721–724
   PubMedGoogle Scholar
• Jubrias S A, Bennett R M, Klug G A. Increased incidence of a resonance in the phosphodiester region of 31P nuclear magnetic resonance spectra in the skeletal muscle of FMS patients. Arthritis Rheum 1994; 37: 801–807
   PubMed Web of Science ®Google Scholar
• Arendt-Nielsen L, Graven-Nielsen T. Central sensitization in FMS and other musculoskeletal disorders. Curr Pain Headache Rep 2003; 7(5)355–361
   PubMedGoogle Scholar
• Lund E, Kendall S A, Janerot-Sjoberg B, Bengtsson A. Muscle metabolism in FMS studied by P-31 magnetic resonance spectroscopy during aerobic and anaerobic exercise. Scand J Rheumatol 2003; 32(3)138–145
   PubMed Web of Science ®Google Scholar
• Sprott H, Rzanny R, Reichenbach J R, Kaiser W A, Hein G, Stein G. 31P magnetic resonance spectroscopy in fibromyalgic muscle. Rheumatology [Oxford] 2000; 39(10)1121–1125
   PubMedGoogle Scholar
• Park J H, Niermann K J, Olsen N. Evidence for metabolic abnormalities in the muscles of patients with Fibromyalgia. Curr Rheumatol Rep 2000; 2(2)131–140
   PubMedGoogle Scholar
• Park J H, Phothimat P, Oates C T, Hernanz-Schulman M, Olsen N J. Use of P-31 magnetic resonance spectroscopy to detect metabolic abnormalities in muscles of patients with fibromyalgia. Arthritis Rheum 1998; 41(3)406–413
   PubMed Web of Science ®Google Scholar
• Vogl T J, Sollner O, Dadashi A R, Reimers C D, Banzer D, Felix R. The value of in-vivo 31-phosphorus spectroscopy in the diagnosis of generalized muscular diseases. The clinical results and the differential diagnostic aspects. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1995; 162(6)455–463
   Google Scholar
• Waters D L, Brooks W M, Qualls C R, Baumgartner R N. Skeletal muscle mitochondrial function and lean body mass in healthy exercising elderly. Mech Ageing Dev 2003; 124(3)301–309
   PubMedGoogle Scholar
• Younkin D P, Berman P, Sladky J, Chee C, Bank W, Chance B. 31P NMR studies in Duchenne muscular dystrophy: Age-related metabolic changes. Neurology 1987; 37: 165–169
   PubMedGoogle Scholar
• Graven-Nielsen T, Mense S. The peripheral apparatus of muscle pain: Evidence from animal and human studies. Clin J Pain 2001; 17(1)2–10
   PubMed Web of Science ®Google Scholar
• Bennett R M, Jacobsen S. Muscle function and origin of pain in fibromyalgia. Bailliere's Clinical Rheumatology 1994; 8(4)721–746
   PubMedGoogle Scholar
• Aiken J, Bua E, Cao Z, Lopez M, Wanagat J, McKenzie D, McKiernan S. Mitochondrial DNA deletion mutations and sarcopenia. Ann N Y Acad Sci 2002; 959: 412–423
   PubMedGoogle Scholar
• Vives-Bauza C, Gamez J, Roig M, Briones P, Cervera C, Solano A, Montoya J, Andreu A L. Exercise intolerance resulting from a muscle-restricted mutation in the mitochondrial tRNA(Leu (CUN)) gene. Ann Med 2001; 33(7)493–496
   PubMed Web of Science ®Google Scholar
• Kovalenko S A, Kopsidas G, Kelso J M, Linnane A W. Deltoid human muscle mtDNA is extensively rearranged in old age subjects. Biochem Biophys Res Commun 1997; 232(1)147–152
   PubMedGoogle Scholar
• Fayet G, Jansson M, Sternberg D, Moslemi A R, Blondy P, Lombes A, Fardeau M, Oldfors A. Ageing muscle: Clonal expansions of mitochondrial DNA point mutations and deletions cause focal impairment of mitochondrial function. Neuromuscul Disord 2002; 12(5)484–493
   PubMedGoogle Scholar
• Sprott H, Salemi S, Gay R E, Bradley L A, Alarcon G S, Oh S J, Michel B A, Gay S. Increased DNA fragmentation and ultrastructural changes in fibromyalgic muscle fibres. Ann Rheum Dis 2004; 63(3)245–251
   PubMedGoogle Scholar
• Watkins L R, Wiertelak E P, Goehler L E, Smith K P, Martin D, Maier S F. Characterization of cytokine-induced hyperalgesia. Brain Res 1994; 654(1)15–26
   PubMedGoogle Scholar
• Vassilopoulos D, Calabrese L H. Rheumatic manifestations of hepatitis C infection. Curr Rheumatol Rep 2003; 5(3)200–204
   PubMedGoogle Scholar
• Capuron L, Hauser P, Hinze-Selch D, Miller A H, Neveu P J. Treatment of cytokine-induced depression. Brain Behav Immun 2002; 16(5)575–580
   PubMedGoogle Scholar
• Watkins L R, Maier S F. Implications of immune-to-brain communication for sickness and pain. Proc Natl Acad Sci U S A 1999; 96(14)7710–7713
   PubMed Web of Science ®Google Scholar
• Watkins L R, Milligan E D, Maier S F. Glial activation: A driving force for pathological pain. Trends Neurosci 2001; 24(8)450–455
   PubMed Web of Science ®Google Scholar
• Wallace D J, Linker-Israeli M, Hallegua D, Silverman S, Silver D, Weisman M H. Cytokines play an aetiopathogenetic role in fibromyalgia: A hypothesis and pilot study. Rheumatology [Oxford] 2001; 40(7)743–749
   PubMed Web of Science ®Google Scholar
• Gur A, Karakoc M, Nas K, Remzi Cevik, Denli A, Sarac J. Cytokines and depression in cases with fibromyalgia. J Rheumatol 2002; 292: 358–361
   Google Scholar
• Arici A. Local cytokines in endometrial tissue: The role of interleukin-8 in the pathogenesis of endometriosis. Ann N Y Acad Sci 2002; 955: 101–9, [discussion 118, 396–406]
   PubMed Web of Science ®Google Scholar
• Bajaj P, Bajaj P, Madsen H, Arendt-Nielsen L. Endometriosis is associated with central sensitization: A psychophysical controlled study. J Pain 2003; 4(7)372–380
   PubMed Web of Science ®Google Scholar
• Trysberg E, Carlsten H, Tarkowski A. Intrathecal cytokines in systemic lupus erythematosus with central nervous system involvement. Lupus 2000; 9(7)498–503
   PubMed Web of Science ®Google Scholar
• Obata K, Noguchi K. MAPK activation in nociceptive neurons and pain hypersensitivity. Life Sci 2004; 742(1)2643–2653
   Google Scholar
• Kwon D, Fuller A C, Palma J P, Choi I H, Kim B S. Induction of chemokines in human astrocytes by picornavirus infection requires activation of both AP-1 and NF-kappa B. Glia 2004; 45(3)287–296
   PubMedGoogle Scholar
• Puma C, Danik M, Quirion R, Ramon F, Williams S. The chemokine interleukin-8 acutely reduces Ca2+] currents in identified cholinergic septal neurons expressing CXCR1 and CXCR2 receptor mRNAs. J Neurochem 2001; 78(5)960–971
   PubMedGoogle Scholar
• Wieseler-Frank J, Maier S F, Watkins L R. Glial activation and pathological pain. Neurochem Int 2004; 45(2–3)389–395
   PubMed Web of Science ®Google Scholar
• Watkins L R, Milligan E D, Maier S F. Glial proinflammatory cytokines mediate exaggerated pain states: implications for clinical pain. Adv Exp Med Biol 2003; 521: 1–21
   PubMed Web of Science ®Google Scholar
• Calis M, Gokce C, Ates F, Ulker S, Izgi H B, Demir H, Kirnap M, Sofuoglu S, Durak A C, Tutus A, Kelestimur F. Investigation of the hypothalamo-pituitary-adrenal axis [HPA] by 1 microg ACTH test and metyrapone test in patients with primary FMS syndrome. J Endocrinol Invest 2004; 27(1)42–46
   PubMed Web of Science ®Google Scholar
• Crofford L J, Young E A, Engleberg N C, Korszun A, Brucksch C B, McClure L A, Brown M B, Demitrack M A. Basal circadian and pulsatile ACTH and cortisol secretion in patients with FMS and/or chronic fatigue syndrome. Brain Behav Immun 2004; 18(4)314–325
   PubMedGoogle Scholar
• Paiva E S, Deodhar A, Jones K D, Bennett R. Impaired growth hormone secretion in FMS patients: Evidence for augmented hypothalamic somatostatin tone. Arthritis Rheum 2002; 46(5)1344–1350
   PubMed Web of Science ®Google Scholar
• Corsello S M, Tofani A, Della Casa S, Sciuto R, Rota C A, Colasanti S, Bini A, Barini A, Barbarino A. Activation of cholinergic tone by pyridostigmine reverses the inhibitory effect of CRH on GHRH induced growth hormone secretion. Acta Endo 1992, (126): 113–116
   Google Scholar
• Dinan T G, O'Keane V, Thakore J. Pyridostigmine induced growth hormone release in mania: Focus on the cholinergic/somatostatin system. Clin Endocrinol [Oxf] 1994; 40(1)93–96
   PubMedGoogle Scholar
• Giusti M, Marini G, Sessarego P, Peluffo F, Valenti S, Caratti C, Giordano G. Effect of cholinergic tone on growth hormone-releasing hormone-induced secretion of growth hormone in normal aging. Aging [Milano] 1992; 4(3)231–237
   PubMedGoogle Scholar
• Hanew K, Utsumi A, Sugawara A, Shimizu Y, Ikeda H, Abe K. The evaluation of hypothalamic somatostatin tone using pyridostigmine and thyrotropin releasing hormone in patients with acromegaly. J Endocrinol Invest 1994; 17(5)313–321
   PubMedGoogle Scholar
• Liao N, Vaudry H, Pelletier G. Neuroanatomical connections between corticotropin-releasing factor [CRF] and somatostatin [SRIF] nerve endings and thyrotropin-releasing hormone [TRH] neurons in the paraventricular nucleus of rat hypothalamus. Peptides 1992; 13(4)677–680
   PubMedGoogle Scholar
• Rivier C, Vale W. Involvement of corticotropin-releasing factor and somatostatin in stress-induced inhibition of growth hormone secretion in the rat. Endocrinology 1985; 117(6)2478–2482
   PubMedGoogle Scholar
• Raj S R, Brouillard D, Simpson C S, Hopman W M, Abdollah H. Dysautonomia among patients with fibromyalgia: A noninvasive assessment. J Rheumatol 2000; 27(11)2660–2665
   PubMedGoogle Scholar
• Martinez-Lavin M, Hermosillo A G, Mendoza C, Ortiz R, Cajigas J C, Pineda C, Nava A, Vallejo M. Orthostatic sympathetic derangement in subjects with fibromyalgia. J Rheumatol 1997; 24(4)714–718
   PubMed Web of Science ®Google Scholar
• Cohen H, Neumann L, Shore M, Amir M, Cassuto Y, Buskila D. Autonomic dysfunction in patients with fibromyalgia: Application of power spectral analysis of heart rate variability [see comments]. Semin Arthritis Rheum 2000; 29(4)217–227
   PubMed Web of Science ®Google Scholar
• Friederich H C, Schellberg D, Mueller K, Bieber C, Zipfel S, Eich W. Stress and autonomic dysregulation in patients with FMS syndrome. Schmerz 2004
   Google Scholar
• Martinez-Lavin M, Hermosillo A G. Autonomic nervous system dysfunction may explain the multisystem features of FMS [editorial. comment]. Semin Arthritis Rheum 2000; 29(4)197–199
   PubMed Web of Science ®Google Scholar
• Martinez-Lavin M. Is FMS a generalized reflex sympathetic dystrophy?. Clin Exp Rheumatol 2001; 19(1)1–3
   PubMedGoogle Scholar
• Martinez-Lavin M, Lopez S, Medina M, Nava A. Use of the Leeds assessment of neuropathic symptoms and signs questionnaire in patients with fibromyalgia. Semin Arthritis Rheum 2003; 32(6)407–411
   PubMedGoogle Scholar
• Martinez- Lavin M, Vidal M, Barbosa R E, Pineda C, Casanova J M, Nava A. Norepinephrine-evoked pain in fibromyalgia. A randomized pilot study [ISRCTN70707830]. BMC Musculoskelet Disord 2002; 3(1)2
   PubMedGoogle Scholar
• Absi M, Petersen K L. Blood pressure but not cortisol mediates stress effects on subsequent pain perception in healthy men and women. Pain 2003; 106(3)285–295
   PubMedGoogle Scholar
• Campbell T S, Ditto B, Seguin J R, Sinray S, Tremblay R E. Adolescent pain sensitivity is associated with cardiac autonomic function and blood pressure over 8 years. Hypertension 2003; 41(6)1228–1233
   PubMedGoogle Scholar
• Absi M, Petersen K L, Wittmers L E. Blood pressure but not parental history for hypertension predicts pain perception in women. Pain 2000; 88(1)61–68
   PubMedGoogle Scholar
• Guasti L, Gaudio G, Zanotta D, Grimoldi P, Petrozzino M R, Tanzi F, Bertolini A, Grandi A M, Venco A. Relationship between a genetic predisposition to hypertension, blood pressure levels and pain sensitivity. Pain 1999; 82(3)311–317
   PubMedGoogle Scholar
• Okifuji A, Turk D C. Stress and psychophysiological dysregulation in patients with FMS syndrome. Appl Psychophysiol Biofeedback 2002; 27(2)129–141
   PubMedGoogle Scholar
• Pellegrino M J, Waylonis G W, Sommer A. Familial occurrence of primary fibromyalgia. Arch Phys Med Rehabil 1989; 70: 61–63
   PubMedGoogle Scholar
• Buskila D, Neumann L, Hazanov I, Carmi R. Familial aggregation in the FMS syndrome. Semin Arthritis Rheum 1996; 26: 605–611
   PubMed Web of Science ®Google Scholar
• Offenbaecher M, Glatzeder K, Ackenheil M. Self-reported depression, familial history of depression and FMS [FM], and psychological distress in patients with FM. Z Rheumatol 1998; 57(Suppl 2)94–96
   PubMedGoogle Scholar
• Arnold L M, Hudson J I, Hess E V, Ware A E, Fritz D A, Auchenbach M B, Starck L O, Keck P E, Jr. Family study of fibromyalgia. Arthritis Rheum 2004; 50(3)944–952
   PubMed Web of Science ®Google Scholar
• Ehrlich G E. Pain is real. FMS isn't. J Rheumatol 2003; 30(8)1666–1667
   PubMedGoogle Scholar
• Owens M J, Nemeroff C B. Role of serotonin in the pathophysiology of depression: Focus on the serotonin transporter. Clin Chem 1994; 40: 288–295
   PubMed Web of Science ®Google Scholar
• Cohen H, Buskila D, Neumann L, Ebstein R P. Confirmation of an association between FMS and serotonin transporter promoter region [5-HTTLPR] polymorphism, and relationship to anxiety-related personality traits. Arthritis Rheum 2002; 46(3)845–847
   PubMedGoogle Scholar
• Offenbaecher M, Bondy B, de Jonge S, Glatzeder K, Kruger M, Schoeps P, Ackenheil M. Possible association of FMS with a polymorphism in the serotonin transporter gene regulatory region. Arthritis Rheum 1999; 42(11)2482–2488
   PubMedGoogle Scholar
• Gursoy S. Absence of association of the serotonin transporter gene polymorphism with the mentally healthy subset of FMS patients. Clin Rheumatol 2002; 21(3)194–197
   PubMedGoogle Scholar
• Gursoy S, Erdal E, Herken H, Madenci E, Alasehirli B. Association of T102C polymorphism of the 5-HT2A receptor gene with psychiatric status in FMS syndrome. Rheumatol Int 2001; 21(2)58–61
   PubMedGoogle Scholar
• Zubieta J K, Heitzeg M M, Smith Y R, Bueller J A, Xu K, Xu Y, Koeppe R A, Stohler C S, Goldman D. COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science 2003; 299(5610)1240–1243
   PubMed Web of Science ®Google Scholar
• Gursoy S, Erdal E, Herken H, Madenci E, Alasehirli B, Erdal N. Significance of catechol-O-methyltransferase gene polymorphism in FMS syndrome. Rheumatol Int 2003; 23(3)104–107
   PubMedGoogle Scholar
• De Andres J, Cerda-Olmedo G, Valia J C, Monsalve V, Lopez A, Minguez A. Use of botulinum toxin in the treatment of chronic myofascial pain. Clin J Pain 2003; 19(4)269–275
   PubMedGoogle Scholar
• Dodick D, Blumenfeld A, Silberstein S D. Botulinum neurotoxin for the treatment of migraine and other primary headache disorders. Clin Dermatol 2004; 22(1)76–81
   PubMedGoogle Scholar
• Lang A M. A preliminary comparison of the efficacy and tolerability of botulinum toxin serotypes A and B in the treatment of myofascial pain syndrome: A retrospective, open-label chart review. Clin Ther 2003; 25(8)2268–2278
   PubMedGoogle Scholar
• Mense S. Neurobiological basis for the use of botulinum toxin in pain therapy. J Neurol 2004; 251(Suppl 1)7–17
   Google Scholar
• Aoki K R. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache 2003; 43(Suppl 1)S9–15
   PubMed Web of Science ®Google Scholar
• Kramer H H, Angerer C, Erbguth F, Schmelz M, Birklein F. Botulinum Toxin A reduces neurogenic flare but has almost no effect on pain and hyperalgesia in human skin. J Neurol 2003; 250(2)188–193
   PubMedGoogle Scholar
• Dolly O. Synaptic transmission: Inhibition of neurotransmitter release by botulinum toxins. Headache 2003; 43(Suppl 1)S16–24
   PubMedGoogle Scholar
• Hong C Z. New trends in myofascial pain syndrome. Zhonghua Yi Xue Za Zhi [Taipei] 2002; 65(11)501–512
   PubMedGoogle Scholar
• Simons D G, Hong C Z, Simons L S. Endplate potentials are common to midfiber myofacial trigger points. Am J Phys Med Rehabil 2002; 81(3)212–222
   PubMed Web of Science ®Google Scholar
• Rivner M H. The neurophysiology of myofascial pain syndrome. Curr Pain Headache Rep 2001; 5(5)432–440
   PubMedGoogle Scholar
• Audette J F, Wang F, Smith H. Bilateral activation of motor unit potentials with unilateral needle stimulation of active myofascial trigger points. Am J Phys Med Rehabil 2004; 83(5)368–74, quiz
   PubMed Web of Science ®Google Scholar
• Edwards J, Knowles N. Superficial dry needling and active stretching in the treatment of myofascial pain-A randomised controlled trial. Acupunct Med 2003; 21(3)80–86
   PubMedGoogle Scholar
• Chen J T, Chung K C, Hou C R, Kuan T S, Chen S M, Hong C Z. Inhibitory effect of dry needling on the spontaneous electrical activity recorded from myofascial trigger spots of rabbit skeletal muscle. Am J Phys Med Rehabil 2001; 80(10)729–735
   PubMed Web of Science ®Google Scholar
• Tuzun E H, Albayrak G, Eker L, Sozay S, Daskapan A. A comparison study of quality of life in women with FMS and myofascial pain syndrome. Disabil Rehabil 2004; 26(4)198–202
   PubMed Web of Science ®Google Scholar